Pixelgen Technologies Secures $12.5 Million to Revolutionize Single-Cell Protein Analysis

Pixelgen Technologies AB is excited to announce a major milestone in its journey to transform precision medicine, having successfully raised $12,500,000 in its latest funding round.

Based in Stockholm, Sweden, and founded in 2020 by a team of visionary innovators and entrepreneurs, Pixelgen is committed to delivering biology at the highest resolution.

This infusion of capital will empower the company to further develop and expand its groundbreaking Proximity Network Assay—a patented technology that enables nanoscale spatial analysis of immune cell proteins.

By deciphering the protein interactomics of single cells in unprecedented ways, Pixelgen’s Proximity Network Assay is at the forefront of a new era in cellular analysis.

The funds will be strategically directed towards enhancing the Pixelgen Proxiome Kit, an advanced tool designed for precision medicine that serves as a cornerstone for translational research in immunology, hematology, and emerging cell therapies.

The company's mission to understand the molecular basis of cellular function will benefit enormously from this investment, which is poised to accelerate advances in our understanding of immune cell behavior at ultra-high capacity.

With this financial boost, Pixelgen plans to scale its operations, drive innovation through cutting-edge research, and expand its portfolio of products that have the potential to revolutionize how diseases are diagnosed and treated.

This investment not only underscores the confidence of venture-backed investors in Pixelgen’s pioneering technology but also marks a significant step towards creating powerful tools that advance healthcare at the cellular level.

Pixelgen Technologies’ commitment to excellence and its enduring dedication to the integration of biology and technology continue to lay a solid foundation for future breakthroughs in precision medicine.